Opposing lineage specifiers induce a pro-tumor hybrid-identity state in lung adenocarcinoma [RNA-seq]
RNA-seq (gene expression) · human · 34 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 34 samples: 17 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinomaGenes & development · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE281963_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1186331 and SRA study SRP545353. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 34 samples.
How we read this: 17 replicated groups read from 34 sample titles; they account for 34 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8633670 3154_EtOH_Replicate1 3154_EtOH
- GSM8633671 3154_EtOH_Replicate2 3154_EtOH
- GSM8633672 3154_4OHT_Replicate1 3154_4OHT
- GSM8633673 3154_4OHT_Replicate2 3154_4OHT
- GSM8633674 H1651_NoDox_Replicate1 H1651_NoDox
- GSM8633675 H1651_NoDox_Replicate2 H1651_NoDox
- GSM8633676 H1651_Dox_Replicate1 H1651_Dox
- GSM8633677 H1651_Dox_Replicate2 H1651_Dox
- GSM8633682 1027B_Control_Replicate1 1027B_Control
- GSM8633683 1027B_Control_Replicate2 1027B_Control
- GSM8633684 1027B_MEKi_Replicate1 1027B_MEKi
- GSM8633685 1027B_MEKi_Replicate2 1027B_MEKi
- GSM8633686 1027B_KRASi_Replicate1 1027B_KRASi
- GSM8633687 1027B_KRASi_Replicate2 1027B_KRASi
- GSM8633688 H1651_Control_Replicate1 H1651_Control
- GSM8633689 H1651_Control_Replicate2 H1651_Control
- GSM8633690 H1651_MEKi_Replicate1 H1651_MEKi
- GSM8633691 H1651_MEKi_Replicate2 H1651_MEKi
- GSM8633692 H358_Control_Replicate1 H358_Control
- GSM8633693 H358_Control_Replicate2 H358_Control
- GSM8633694 H358_MEKi_Replicate1 H358_MEKi
- GSM8633695 H358_MEKi_Replicate2 H358_MEKi
- GSM8633696 3154_EtOH_Control_Replicate1 3154_EtOH_Control
- GSM8633697 3154_EtOH_Control_Replicate2 3154_EtOH_Control
- GSM8633698 3154_EtOH_KRASi_Replicate1 3154_EtOH_KRASi
- GSM8633699 3154_EtOH_KRASi_Replicate2 3154_EtOH_KRASi
- GSM8633700 3154_4OHT_Control_Replicate1 3154_4OHT_Control
- GSM8633701 3154_4OHT_Control_Replicate2 3154_4OHT_Control
- GSM8633702 3154_4OHT_KRASi_Replicate1 3154_4OHT_KRASi
- GSM8633703 3154_4OHT_KRASi_Replicate2 3154_4OHT_KRASi
- GSM8960299 3311_Control_Replicate1 3311_Control
- GSM8960300 3311_Control_Replicate2 3311_Control
- GSM8960301 3311_MEKi_Replicate1 3311_MEKi
- GSM8960302 3311_MEKi_Replicate2 3311_MEKi
- GSE281961 Opposing lineage specifiers induce a pro-tumor hybrid-identity state in lung adenocarcinoma [ChIP-seq] 60 samples shares hybrid-identity, adenocarcinoma, specifiers, pro-tumor, opposing, lineage, induce
- GSE115462 TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma (RNA-seq) 42 samples shares adenocarcinoma, rna-seq
- GSE266364 Immunogenic cell death inducer cEmsy boosted cancer immunotherapy in lung adenocarcinoma 33 samples shares adenocarcinoma, induce
- GSE282765 Eosinophils restrict CRC metastasis by inhibiting pro-tumorigenic Spp1+ macrophage differentiation. 42 samples shares pro-tumor
- GSE235246 Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma impair CD8+ T cell activation and responsiveness to immunotherapy in mice 38 samples shares adenocarcinoma
- GSE336609 KRAS inhibition is an effective therapy for appendiceal adenocarcinoma 22 samples shares adenocarcinoma
- GSE235233 Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma suppress CD8+ T cell activation and inhibit response to immune checkpoint therapy [Cultured_Human_Mouse] 16 samples shares adenocarcinoma
- GSE315628 Single-cell data for FGFR3-driven gene regulatory network analysis reveals a pro-tumoral role for p63 in luminal bladder tumors 6 samples shares pro-tumor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.